DescriptionAs haemophilia is a life-long condition, continuing supervision by a group of medical personnel is required. In many countries this is provided by comprehensive care haemophilia centres where staff of all specialities concerned with treatment- haematologists, paediatricians, nurses, physiotherapists, orthopaedic surgeons - have specialized knowledge.
This new book is a definitive resource on the current aspects and issues around haemophilia. Complications of haemophilia care are well covered in chapters on inhibitors, and musculoskeletal problems, as are all the latest developments in the field of haemophilia.
Part 1: INTRODUCTION.
1 History of Hemophilia (Caroline Cromwell and Louis Aledort).
2 Hemophilia Care in the Modern World (Christine A. Lee).
3 Comprehensive Care Model in Hemophilia (Prasad Mathew).
Part 2: GENERAL TOPICS.
4 When Should We Switch From On-Demand to Prophylaxis Regimen? (José A. Aznar, Andres Moret, Lydia Abad-Franch, Ana Rosa Cid, Saturnino Haya and Felipe Querol).
5 Prophylaxis in Children (M. Manco-Johnson).
6 Prophylaxis in Adults with Hemophilia (Victor Jiménez -Yuste, Emérito-Carlos Rodríguez-Merchán, Maria-Teresa Alvarez-Román, Monica Martín –Salces).
7 The Economics of Prophylaxis: Does Prophylaxis with Clotting Factor Represent Value for Money? (Alec Miners).
8 The Transition of Care for the Young Adult Hemophilia Patient (Pia Petrini).
9 Perinatal Clinical Care and Molecular Diagnosis in Hemophilia (Carmen Altisent and Francisco Vidal).
10 Managing the Mature Person with Hemophilia (Savita Rangarajan and Thynn Thynn Yee).
11 Quality of Life in Hemophilia (Eduardo Remor).
Part 3: INHIBITORS.
12 Immunology of Inhibitor Development (Birgit M Reipert, Christoph J Hofbauer, Katharina N Steinitz, Hans-Peter Schwarz, FM Horling).
13 Epidemiology of Inhibitors (Johanna G. Van der Bom)
14 Early Tolerisation to Minimise Inhibitors in PUPS with Hemophilia A (Günter Auerswald and Karin Kurnik).
15 Prediction of Inhibitors in Severe Hemophilia (H. Marijke van den Berg and Kathelijn Fischer).
16 Genetic basis for Inhibitor Development (Johannes Oldenburg and Anna Pavlova).
17 Non-Genetic Risk Factors for Inhibitor Development (Lisa N. Boggio and Mindy L. Simpson).
Part 4: INHIBITOR TREATMENT.
18 Immune Tolerance Induction Programmes (Jan Blatny and Prasad Mathew).
19 Prophylaxis in Hemophilia A Patients with Inhibitors (Leonard A. Valentino and Guy Young).
20 Treatment of Bleeding in FVIII Inhibitor Patients (Paul Giangrande and Jerome Teitel).
21 Discordancy of By-Passing Therapy (Jan Astermark).
Part 5: JOINT HEALTH AND DISEASE.
22 Experimental Studies on Hemarthrosis, Synovitis and Arthropathy (Leonard A. Valentino and Narine Hakobyan).
23 Assessment of Joint Involvement in Hemophilia (Erik Berntorp).
24 Imaging of the Hemophilic Joint (Carmen Martín-Hervásand Emérito-Carlos Rodríguez-Merchán).
25 Initial and Advanced Stages of Hemophilic Arthropathy, and Other Musculo-Skeletal Problems: the Role of Orthopedic Surgery (Emérito-Carlos Rodríguez-Merchán, VictorJiménez -Yuste and Nicholas J. Goddard).
26 Perioperative Thromboprophylaxis for Persons with Hemophilia Undergoing Orthopaedic Surgery (Gerry Dolan, Donna M. Dimichele and Emérito-Carlos Rodríguez-Merchán).
Part 6: NEW DEVELOPMENTS.
27 New Technologies for the Pharmacokinetic Improvement of Coagulation Factor Proteins (Leonard A. Valentino).
28 Current and Future Approaches to Gene Therapy in Patients with Hemophilia (Maria-Teresa Alvarez- Román, Monica Martín-Salces, Victor Jiménez -Yuste and Emérito-Carlos Rodríguez-Merchán).
29 New Developments in Hemophilic Arthropathy (Emérito-Carlos Rodríguez-Merchán and Leonard A. Valentino).
30 Physiotherapy Evaluation and Intervention in the Acute Hemarthrosis: Challenging the Paradigm (Nichan Zourikian and Angela L. Forsyth).
31 Laboratory Assays to Predict Response to Bypassing Agents (Benny Sørensen and Claude Negrier).
32 Combination/Sequential Use of Bypassing Agents (Alessandro Gringeri).